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SynPharm: A Guide to PHARMACOLOGY Database Tool for
Designing Drug Control into Engineered Proteins
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Joanna L. Sharman, and Jamie A. Davies
Centre for Discovery Brain Sciences, Deanery for Biomedical Sciences, University of Edinburgh, Edinburgh EH8 9XD, U.K.
ABSTRACT: A major challenge in synthetic biology, particularly for mammalian systems, is
the inclusion of adequate external control for the synthetic system activities. Control at the
transcriptional level can be achieved by adaptation of bacterial repressor−operator systems
(e.g., TetR), but altering the activity of a protein by controlling transcription is indirect and for
longer half-life mRNAs, decreasing activity this way can be inconveniently slow. Where
possible, direct modulation of protein activity by soluble ligands has many advantages,
including rapid action. Decades of drug discovery and pharmacological research have
uncovered detailed information on the interactions between large numbers of small molecules
and their primary protein targets (as well as off-target secondary interactions), many of which
have been well studied in mammals, including humans. In principle, this accumulated
knowledge would be a powerful resource for synthetic biology. Here, we present SynPharm, a
tool that draws together information from the pharmacological database GtoPdb and the
structural database, PDB, to help synthetic biologists identify ligand-binding domains of
natural proteins. Consequently, as sequence cassettes, these may be suitable for building into
engineered proteins to confer small-molecule modulation on them. The tool has ancillary utilities which include assessing
contact changes among different ligands in the same protein, predicting possible effects of genetic variants on binding residues,
and insights into ligand cross-reactivity among species.
■ INTRODUCTION
Synthetic biology is a technology for engineering of new
biological functions through the construction of novel genetic
networks to realize novel metabolic, signaling, and devel-
opmental pathways.1−5 Some synthetic biological systems use
only natural proteins (i.e., as represented by the Swiss-Prot
canonical sequence for that species) or achieve novel functions
by combining proteins not normally found in the same cell or
even the same species. Other systems involve the use of novel
proteins, themselves typically including domains chosen from
various natural proteins and coded into an engineered gene: an
example is the SynNotch synthetic cell−cell signaling system.6
In many applications, there is a clear need for synthetic
biological devices to be subject to external controls, for
example, to create adequate safeguards and to exert temporal
and/or spatial control on a particular system. This need is
particularly acute when the device is intended to be used in the
general environment or in a medical implant. At the very least,
there needs to be a reliable means to shut the system down
quickly, and much thought is being given to this problem.7,8
Most control systems used to date have operated by using
small molecules to control gene transcription. Typically, they
use antibiotic-sensitive transcriptional repressor proteins from
bacterial systems, the operator sites of which are fused to the
promoter of the synthetic gene: the well-known tetR system is
a much-used example.9 These systems work well but their
effect on protein activity is very indirect, blocking transcription
of further mRNA for a protein but not affecting existing
molecules of the protein itself nor of the mRNA from which
new protein molecules will be translated. Constitutive
differences in mRNA half-lives can, however, limit this
approach for particular proteins.10 Direct control of protein
activity would be faster, which is why this dominates natural
inter- and intracellular signaling. For synthetic circuits, control
by rapidly diffusing small molecules would be particularly
useful and several novel controls of this type have been
constructed, generally by a laborious process of selection from
large libraries of protein variants.11,12
As modulators of activity, small molecules have many
advantages over alternative forms of experimental functional
modulation, such as CRISPR, RNAi, and antibody blocking.
Principal advantages of these are as follows: (a) rapid action;
(b) dose response can be used to vary the effects
quantitatively; (c) reversal by wash-out; (d) use of equal and
low-potency analogues with different chemotypes as specificity
and reproducibility controls; (e) although less common,
activators or agonists may be suitable for positive modulation
(i.e., gain-of-function interventions); (f) allosteric modulators
offer a different type of kinetic control; and (g) small
molecules can be accurately measured both pre and post
experiment (e.g., to monitor input dosing and metabolic
degradation).
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The need for pharmacological researchers to access data for
the interactions between druglike molecules and their protein
targets has resulted in the production of a range of databases
aligned to this general task, starting with BindingDB in 2001.13
Updates on these resources have recently been reviewed.14
These databases present valuable sources of information that
might help synthetic biologists identify drug−protein pairs in
which the drug-binding site of the protein is small and self-
contained enough to be used as a “module” that will confer
drug control on engineered proteins. This would allow rapid
and direct modulation of the activity of the protein without the
lag times involved in transcription, translation, and degrada-
tion. The use of an approved drug as the controlling ligand
would bring the additional advantage in that safety aspects of
clinical drugs, and their possible off-target side effects, are
generally well established. This makes the approach partic-
ularly valuable if the synthetic biological constructs are
eventually to be translated into in vivo, clinical, or animal-
agricultural contexts. However, attempting such module
selection from large-scale chemogenomic databases such as
BindingDB,15 ChEMBL,16 and even directly from PDB17
would be challenging. Various types of PDB abstractions such
as the sc-PDB ligand-binding database18 and PDBbind19 are
also useful resources but have long update cycles.
To make navigating these complex datasets easier, we have
created a web-based tool that integrates pharmacological and
protein-binding information as a first-stop entry point for the
drug-binding domains of selected proteins in a manner useful
to synthetic biologists. The interface we designed supports a
variety of searching and browsing strategies and facilitates the
choosing of the most appropriate protein domain to be used as
a controllable module for a particular purpose. This
functionality, that we have named SynPharm, has been
integrated as a tool within the IUPHAR/BPS Guide to
PHARMACOLOGY database (GtoPdb), an expert-curated,
open-access database by the International Union of Basic and
Clinical Pharmacology.20 This was chosen for the following
reasons:
1. It is embedded in an environment with an active
experimental synthetic biology team. This means that
the initial bioinformatics in vitro testing cycles are
already in progress (and the latter will feed back to
enhancements of the former).
2. GtoPdb has a relatively rapid release cycle of
approximately 2 months, and it is intended to
synchronize SynPharm updates.
3. Relative to the larger resources our less broad-ranging
but pharmacologically selective PDB mappings present
much smaller sets for users to easily navigate but still
capture approved drugs and clinical candidates.
4. Every ligand in SynPharm is expert-curated and activity-
mapped even though this activity is not always explicitly
referenced in the publication associated with the PDB
entry.
5. This means that our selected ligands are also manually
identified as authentically binding to specific protein
pockets rather than inorganic ions and/or heteroatoms
from crystallization reagents.
6. Partially due to SynPharm but also because of the
increasing interest in new receptor and enzyme ligand
structures in general, we have been recently enhancing
our capture by triaging all new human PDB depositions.
7. Beyond direct application to synthetic biology per se,
SynPharm has ancillary utility for GtoPdb users to
explore ligand structures.
The Results section below presents the web pages that we
have instantiated for SynPharm, the technical construction of
which is described in the “Methods” section.
■ RESULTS
Our ligand-identification process identified 804 ligand−target
interactions that were associated with at least 1 PDB code.
Manually checking these interactionPDB maps and rejecting
duplicates gave a preliminary list of 768 interactions with
associated PDB files. Among the interactions with structural
data, 744 of the 768 (97%) interactions concern human data,
with 15 (2%) rat, 8 (1%) mouse targets, and 1 Plasmodium
falciparum target. The statistics reported, including for the web
page captured in figures, were distilled from GtoPdb release
2018.1. They will thus change with subsequent releases, mainly
from the curation of new PDB ligands but also some cases
where PDB structures with activity data against new targets are
reported.
Our results established (not unexpectedly) that the
distribution of interactions for which there is identifiable
structural data is unevenly distributed among target families, as
shown below in Table 1.
As is well known, some target classes are more tractable to
X-ray determination and consequently proportionally more
highly represented with structural data. For example, nuclear
hormone receptor (NHR) interactions are particularly
structure-dense in comprising 17% of the annotated sequences
but just 3% of GtoPdb interactions overall. Enzymes are also
over-represented in that just 20% of GtoPdb interactions
involve enzymes, but 60% of those proteins with structural
data. By contrast, voltage-gated ion channels (VGICs) have
just 3 annotated sequences (0.5%), compared with 1408 (8%)
total interactions. This bias reflects the inherent difficulties
with structural studies of membrane proteins, although recent
advances have led to an increase in the number of GPCR
Table 1. Representations of Different Classes of Targets in
GtoPdb That Have Any Interaction Data and That Have
Useful Structural Dataa
GtoPdb
target type
targets with
interactions
(with or
without
structures)
number of
interactions
(with or
without
structures)
targets with
structural
data
interactions
with
structures
GPCR 277 (16%) 9078 (52%) 29 (12%) 67 (11%)
enzyme 755 (44%) 3518 (20%) 157 (64%) 365 (60%)
VGIC 127 (7.5%) 1408 (8%) 2 (0.8%) 3 (0.5%)
LGIC 66 (3.9%) 1027 (5.9%) 4 (1.6%) 4 (0.660%)
other ion
channel
47 (2.8%) 201 (1.2%) 0 0
catalytic
receptor
178 (10%) 992 (5.7%) 13 (5.3%) 40 (6.6%)
NHR 35 (2.1%) 523 (3.0%) 25 (10%) 104 (17%)
transporter 120 (7%) 433 (2.5%) 1 (0.4%) 4 (0.66%)
other
protein
99 (5.8%) 231 (1.3%) 16 (6.5%) 23 (3.8%)
aGPCR = G protein-coupled receptors; VGIC = voltage-gated ion
channels; LGIC = ligand-gated ion channels; NHR = nuclear
hormone receptors.
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structures in the last few years, many of which include
ligands.21
Our process of compiling the SynPharm resource, detailed in
the Methods section, is outlined in Figure 1. The output has
been used to populate the home page designed to allow users
to search the dataset by ligand or target protein (Figure 2).
Users may browse the site without a specific molecule in
mind or alternatively take as their starting point identifying any
ligand-binding segment of a protein that might be transferrable
to an engineered protein in their project. In this case, clicking
on the “Sequences” link without entering a search term lists all
target proteins in the list of potentially useful pairs described
above. This list can be browsed as shown in Figure 3.
In Figure 3, targets have been ordered by the length of
ligand-binding segment but they can be ordered by any of the
columns by clicking on the table headers. These metrics can
provide useful first-pass information to prioritize more detailed
analyses. Selecting any target brings the user to its sequence
page. At the head of this page is a three-dimensional
visualization of the target chain bound in complex with the
ligand, with the binding segment itself highlighted in green to
show its context within the original chain (Figure 4A).
The views in Figure 4 provide a rapid visual indication of
how independent of the other features of the protein the
binding segment’s structure is likely to be and thus more
transferable to other proteins. Visualization of the structure
uses the JavaScript PV protein viewer.22 In addition to showing
the structures, the sequence pages present metrics such as
proportional chain length and contact ratio (used as a rough
measure of likelihood that the sequence will fold correctly by
itself, as it is a measure of “domain-likeness”: higher is more
promising). The GtoPdb affinity data for the specific ligand−
target interaction are also provided. Each sequence also has a
residue distance matrix (Figure 4B), which depicts the
Figure 1. Strategy used to produce a database of potentially useful
interactions from known binding data.
Figure 2. SynPharm home page with summary statistics at http://synpharm.guidetopharmacology.org/.
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distances between any two given residues in the binding chain,
with the bind sequence itself highlighted with a black dotted
line. This is to give a sense of the globularity of the sequence
within the chain, and how compact it is.
There is also a feature viewer (Figure 4D) for each
sequence, which utilizes the biojs-vis-protein features viewer.23
In addition to binding residues and secondary structure
elements, the feature viewer also maps hydrophobicity along
the bind sequence, using the Kyte−Doolittle measures of
amino-acid hydrophobicity.24 There are extensive search
functions for identifying sequences or ligands by various
metrics. All ligands have links back to GtoPdb, and a subset of
their data is available directly on the SynPharm page,
particularly molecular data and clinical approval information.
These were chosen because they may be relevant to a
researcher when picking a molecular switch inducer, but the
full range of pharmacological data is accessible via the link back
to GtoPdb. This can be illustrated for BACE1, an aspartyl
protease drug target for Alzheimer’s disease.25 In Figure 5, a
section of the BACE1 entry is shown and Figure 6 shows a
sequence alignment of the extracted ligand interaction sections.
The eight SynPharm entries are indicated in the upper panel.
From the total ligand entries in the lower panel, affinity values
are displayed for three of the SynPharm ligands, compound 16
[PMID: 23412139], AZ-4217, and AMG-8718. The PDB
ligands crystallized in a target are indicate with the red circular
logo intersected with a helix (note that verubecestat did not
pass the SynPharm fault filters but the PDB entry can still be
inspected).
A number of SynPharm advantages can be discerned from
the BACE1 example, particularly because it is one of the most
intensively perused drug targets (reflecting the massive unmet
need for effective Alzheimer’s treatments). Metrics in support
of this are that no less than 364 BACE1 structures are in PDB
(nearly all with ligands), 11 of which were deposited in 2017.
The ChEMBL 23 human BACE1 entry is linked to 6846
structures with some level of activity mapping. The GtoPdb
BACE1 entry maps 21 quantitative ligand interactions with a
focus on clinical candidates and stringently selected research
leads. Of these, 11 are in PDB (indicated with the orange
circular logo) and 5 are not in ChEMBL. From the 11, the 8
indicated in Figures 4 and 5 have passed the SynParm triage
(described in the Methods section) and, as multiple ligands for
the same target, provide a useful calibration.
For example, the alignments shown in Figure 5 indicate
explicit differences among ligand interaction residues for the
set even though the alignment of the sequence sections
indicates they are binding to the same pocket. We can note
that all eight interact with Tyr 132 whereas only 82636
interacts with Glu 134 and Gly 135 and Tyr 137 only interacts
with 78987 and 84541. These differences may be spatially
minor (i.e., possibly only just outside the 5 Å limit used by
SynPharm) but can nonetheless be useful. Even more useful to
the synthetic biologist is to compare the overall length of the
contiguous binding section for particular ligands. In Figure 5,
we can see that five sequences extend out to Ala 396 as the
ultimate interaction point. However, the results also indicate
that only extending to DSGTT (or just past it in cassette
terms) may be sufficient.
Although SynPharm would be sufficient as a stand-alone
tool, there are external resources that complement it. The most
obvious of these are the primary data sources of RCSB PDB
and PDBe, both of which both of which have complementary
features for visualizing ligand binding in a sequence context.
We would also recommend PDBSum for other types of
display.26 These include advanced two-dimensional secondary
structure diagrams, the LIGPLOT display of ligand binding,
and indications of sequence conservation. In cases where there
are many ligands co-crystalized in the same protein (e.g., for
BACE1), the PocketOme encyclopedia of small-molecule
binding sites will give a detailed breakdown of ligand sets.27
For a deep exploration of both sequence- and structure-based
homology, we suggest the Phyre2 web portal for protein
modeling, prediction, and analysis.28 For ligands per se (with
or without PDB entries), we have made another important
utility accessible from within GtoPdb in the form of ChEMBL
Figure 3. Top section of the list served to a user entering the target sequence part of the database. http://synpharm.guidetopharmacology.org/
sequences/.
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outlinks. For BACE1, this means that we were able to find one
of the highest reported potencies for a lead compound with a
0.3 nM IC50 against the purified enzyme (ligand ID 9982,
compound 15 [PMID 25699151]). This would be of interest
to test against an engineered protein despite the absence of a
PDB entry.
■ DISCUSSION
The work described in this paper has resulted in a new open
web resource mainly designed to help synthetic biologists to
engineer pharmacological regulation into their proteins. The
idea of adding regulation into engineered proteins has already
proved itself useful in a variety of contexts. A famous example
is the addition of the tamoxifen-sensitive ERT2 domain into
Figure 4. Examples of the types of structural display found on the sequence details page for human β-secretase 1 in complex with the ligand AMG-
8718 (sequence ID 84541). The top-left panel shows the three-dimensional structure interactive viewer where the binding segment is highlighted in
purple, the rest of the target protein in green, and the ligand is shown in stick view. The top-right panel shows the residue distance matrix. The
distance between any two residues in the target chain is denoted by color, green to red, and, on desktop screens, hovering over any pixel will
provide an exact numerical distance in angstroms of the relevant residues. White portions denote residues missing from the PDB file of origin. The
dotted line indicates the binding sequence. The central panel shows the binding portion of the sequence. The arrows allow the sequence sections to
be extended outward beyond the first and last interaction residues (five are shown on each end in this case) The lower panel shows a zoomed-in
section of the feature viewer. Binding residues are shown in context with secondary structure elements (α-helices and β-strands) and
hydrophobicity over the peptide sequence.
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Cre recombinase to create a drug-inducible gene excision,
allowing experimenters to remove gene function from an
experimental animal at the time of their choosing.29 This has
been used in a variety of applications. Some have used the
system to genetically mark cells for lineage tracing in
development,30,31 disease,32 and regeneration.3,33 Other
applications have used ligand-inducible Cre to examine gene
function by removing it from a cell only at a chosen stage of
development.34,35 Induced Cre-mediated recombination has
also been used to create sarcomas in model animals for the
purposes of studying tumor development.36 The technique has
even been used in anatomical studies, deliberately suboptimal
doses of inducer being used to mark only sparse neuronal cells,
allowing their detailed morphology to be studied in otherwise
unlabeled tissue.37 The use of photocaged estrogen adds an
optogenetic dimension to a version of the system using Cre-ER
instead of Cre-ERT2, allowing light to be used to activate Cre-
ERT2 in specific cells.38
The addition of ligand control is not limited to Cre. A
similar technique has been used to add the ER domain to Snail,
to study the role of that mediator of epithelial−mesenchymal
transitions in controlling fibrosis in adult kidney disease.39 A
recent example of a construct design success using SynParm is
provided by our own work in placing the effectors of CRISPR,
Cas9 and Cpf1, under the control of tamoxifen and
mifepristone (Dominguez-Monedero et al., manuscript sub-
mitted). The impact of these examples establishes that
engineering control into proteins can be useful. It is our
hope that the tools described here will be useful in the
construction of further examples, broadening the range of
ligands that can be used for this type of work.
Several caveats should be taken into consideration with our
approach. One of these is the necessary restriction to
contiguous sections of sequence. However, it is well known
that overall binding energies are likely to have at least some
contribution from long-range secondary structure interactions
within the entire protein structure. Thus, the binding sequence
cassette not only needs to fold correctly within the engineered
host sequence, but it may also have a lower binding constant
and altered kinetics (e.g., Kon and/or Koff) compared with the
full length native counterpart. This also means that the
discontinuous binding sites characteristic of receptors, ion
channels, and transporters are largely excluded from our data
harvest (but the associated ligands are not necessary ruled out
for synthetic applications). Another caveat is that GtoPdb
literature selection focuses on clinical candidates where
optimization often result in a lower potency than the initial
lead compounds. This bias is thus not optimal for ligand-
binding cassettes. Notwithstanding, for in vitro synthetic
biology applications, complementary data can be explored,
including searching for very potent inhibitors that are neither
in GtoPdb nor in the PDB but have a high likelihood of
binding the same sequence section (and this could be
supported by structural superimposition and/or docking
experiments). We note also the caveat that the nesting-in of
active site sections, by definition, could endow the host protein
Figure 5. Snapshot from the GtoPdb BACE1 target entry, with ligands ranked by affinity values. http://www.guidetopharmacology.org/GRAC/
ObjectDisplayForward?objectId=2330.
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with enzyme activity. In such cases, it should be possible to
abolish such unwanted properties by mutating active site
residues that are not major contributors to the binding energy.
Alternatively, because GtoPdb has annotated a number of
allosteric ligands, these noncatalytic binding modules could be
exploited.
Figure 6. Differences in the contact residues extracted for the eight BACE1 ligands. The eight SynPharm sequences (in descending order) are
84891, 78993, 78985, 78477, 78900, 82636, 78987, and 84541. The latter (lowermost) is for AMG-8718 as shown in Figure 3. As for the
SynPharm display, the uppercase letters indicate ligand contact residues.
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We can point out utilities of SynPharm that extend beyond
practical applications to synthetic biology per se. First, the
entries simply act as a convenient flag to users for the existence
of relevant PDB structures, along with the orange logo.
Second, there is increasing interest in the effects of protein
sequence variants that affect protein function in pharmacolog-
ically significant ways, for example, patient drug responses if
substitutions are found in the SynPharm sequences for
individuals and population groups. Third, by adding rodent
or other model organism sequences to the sequence align-
ments shown in Figure 5, insight can be gained into
orthologous cross-reactivity of ligands that could be exper-
imentally tested. An example for BACE1 is that the longest
sequence section from Figure 5 has 82% identity with the
Zebrafish orthologue (UniProt Q6NZT7). Although no
structure of this protein is yet available, the SynPharm results
indicate that there are differences in the vicinity of the binding
residues. Notwithstanding, the similarity suggests that func-
tional perturbations could be carried out (e.g., with compound
15 [PMID 25699151]) in this important model organism for
human disease conditions. Matching ligand-binding sequences
to distant homologs raises the possibility of predicting binding
sites in proteins rather than relying on known ones. Although
this goes beyond the functionality of SynPharm per se, this
could be generally applicable in GtoPdb. Probable binding
pockets of compounds with potent affinities may be
predictable for human paralogues or species orthologues on
the basis of homology modeling (e.g., using Phyre228).
We would be pleased to hear from other teams who would
like to use SynPharm, and we may be able to assist in cross-
checking complementary sources to expedite their choices. In
addition, we would be like to record future examples of success
that we could reference.
■ METHODS
We used a sequential bioinformatic strategy for identifying
ligand-binding sequence sections potentially useful to synthetic
biology (Figure 1). Stage 1 was a screen for targets in GtoPdb
for which any structural ligand-binding data were available in
the form of RCSB PDB files. This screen was performed by
using GtoPdb web services to request PDB codes for each
ligand associated with a target in GtoPdb (2018.1 release). To
obtain further structural data on this first set of potentially
interesting interactions, the RCSB PDB web services were
queried with information from GtoPdb. For each ligand−target
interaction, PDB codes associated with ligands were obtained
by searching on ligand code, name, SMILES, InChI, or peptide
sequence. PDB codes associated with targets were obtained by
searching the RCSB PDB web services using UniProtKB
accessions.
Stage 2 was to identify amino-acid residues on the target that
mediate each of the ligand−target binding interactions. The
residues that mediate the ligand binding were identified by
either using the information in REMARK 800 and SITE
records of the relevant PDB file or, if no such records exist, by
selecting all residues with atoms within 5 Å of a ligand atom
(ignoring hydrogen atoms). The binding sequence was then
defined as the segment of the protein chain that contained all
the ligand-binding residues, for example, a segment between
amino acids 30 and 45 of a protein chain. If binding residues
were on more than one peptide chain of a multipeptide target
protein complex, the interaction was rejected as not being
useful for the purposes of protein engineering. Interactions
were also rejected if more than 5% of the residues in the chain
are “missing”, that is, not observed in the PDB file (according
to REMARK 465 records). This was the most frequent reason
for discarding candidates. Stage 2 cut the list of potentially
useful interactions down to 618 sequences. This is a relatively
small proportion (3.5%) of the number of interactions in the
2018.2 release of GtoPdb, a reflection of the small number of
PDB target−ligand interactions that pass our filtration rules for
SynPharm.
Stage 3 associated certain metrics with each sequence. These
were as follows: (i) its length as a proportion of the original
chain, (ii) its “contact ratio”defined as the ratio of internal
contacts (all nonhydrogen atom pairs within the sequence
within 5 Å of each other, excluding atoms within two covalent
bonds of each other) to external contacts (all nonhydrogen
atom pairs between the sequence and the rest of the chain, less
than 5 Å). In cases where an interaction had multiple PDB
maps and so multiple potential sequences to represent it, we
selected those with the smallest length proportional to their
original chain length as the most likely to be useful for
engineering purposes. The system also allows manual selection
of an interactionPDB map if this is required.
The functions for accessing the GtoPdb web services have
been bundled into a stand-alone Python library called
pyGtoP,40 and the code for parsing PDB files and identifying
the various elements within them (used in sequence
construction) has been bundled into a Python PDB parser
called molecuPy. Both are open source projects viewable on
GitHub. The scripts that used these new libraries to do the
work described above, as well as the code for the database and
web interface itself, are also open source and viewable on
GitHub in the SynPharm repository.41,42
Construction of a Web Interface. Our aim was to make
the data available in a useful format to synthetic biologists, in
the form of an easy-to-use web page. We have therefore stored
the data in a PostgreSQL43 database, with a separate staging
database to make future updates easier. This is connected to a
web page using a Java (Oracle Corporation, Redwood City,
CA) web application installed on an Apache Tomcat web
server (The Apache Software Foundation), and the web page
is open access at ref 44.
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